Veracyte resets Decipher Prostate volume expectations and outlines 2027 view
FROM THE WIRE · SEEKINGALPHA.COM
Earnings Call Insights: Veracyte (VCYT) Q3 2026 MANAGEMENT VIEW * "Third quarter revenue increased approximately 15% year-over-year to $151.8 million, and we delivered another quarter of strong profitability and cash generation." (CEO Marc Stapley) * "Afirma exceeded…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishLower Decipher Prostate volume expectations may weigh on the company's growth outlook.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Third-quarter revenue rose about 15% year over year to $151.8 million.
- 02Decipher Prostate volume was lower than expected, while Afirma exceeded expectations.
- 03Incremental annual volume growth expectations are reset to 12,000-15,000 tests.
- 04The urology team will be expanded by about 30% next year.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets